MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FDA to Evaluate Risk of Drug-Eluting Stents

In efforts to address recent controversy surrounding drug-eluting stents, FDA will be reexamining the safety of these devices.

According to today's Boston Globe, the agency announced the formation of a public panel to evaluate the risk of blood clots in patients who have the stents implanted. FDA also released a statement on its website, which says that the panel, consisting of outside experts, will be looking at studies presented in Atlanta and Barcelona. Recent studies have revealed a small but significant risk of blood clots in patients with drug-eluting stents. The panel's evaluation will also determine if more clinical studies must be performed and whether or not anticoagulants should be used for a longer period of time. Currently, FDA states it believes drug-eluting stents are safe and effective when used for approved indications.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.